Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Accounts Payables (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Accounts Payables readings, the most recent being $869964.0 for Q1 2026.

  • On a quarterly basis, Accounts Payables fell 8.57% to $869964.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $869964.0, a 8.57% decrease, with the full-year FY2025 number at $991169.0, down 12.1% from a year prior.
  • Accounts Payables hit $869964.0 in Q1 2026 for Pharma-Bio Serv, down from $991169.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.7 million in Q3 2022 to a low of $869964.0 in Q1 2026.
  • Median Accounts Payables over the past 5 years was $1.1 million (2024), compared with a mean of $1.3 million.
  • Biggest five-year swings in Accounts Payables: increased 1.54% in 2023 and later tumbled 33.78% in 2024.
  • Pharma-Bio Serv's Accounts Payables stood at $1.6 million in 2022, then decreased by 9.95% to $1.5 million in 2023, then dropped by 23.15% to $1.1 million in 2024, then decreased by 12.1% to $991169.0 in 2025, then dropped by 12.23% to $869964.0 in 2026.
  • The last three reported values for Accounts Payables were $869964.0 (Q1 2026), $991169.0 (Q4 2025), and $874379.0 (Q3 2025) per Business Quant data.